How Adoptive Cell Therapy Works

Our technology is based on TIL isolated from the patient’s tumor following resection. The cells are then expanded to billions in vitro, away from cancer’s immune-suppressing effects. These highly activated, potent TIL are then infused back into the patient, who has been preconditioned to remove all suppressive influences.

NCI Trial DataPublicationsPresentation

NOW ENROLLING

Current Clinical Trials

PHYSICIANS: To learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts.

C-144-01: Metastatic Melanoma

Phase 2 clinical trial to assess the safety, efficacy and feasibility of an adoptive cell therapy based on autologous TIL (LN-144-01), followed by IL-2, in the treatment of patients with refractory metastatic melanoma. The multi-center, single-arm trial is now recruiting patients at various sites in the US.

View

C-145-03: Squamous Cell Carcinoma of the Head and Neck (SCCHN)

A Phase 2, Multicenter Study to Assess the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes (LN-145-03) for Treatment of Patients with Squamous Cell Carcinoma of the Head & Neck.

View

C-145-04: Cervical Carcinoma

A Phase 2, Multicenter, 3-Cohort Study to Assess the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes (LN-145-04) for Treatment of Patients with Cervical Carcinoma.

View